POSTER: ABCL-489: Primary Outcomes From the Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (frontMIND)
Year: 2026
Type: article
Authors: Jason Westin, Georg Lenz, Marek Trnený, John M Burke, Grzegorz S Nowakowski, Christopher P Fox, Annalisa Chiappella, Johannes Duell, Chan Y Cheah, Joseph Z Ye, Priscilla B Caguioa, David Belada, Sung Yong Oh, Sandy Amorim, Andreas Rosenwald, Roberto Chiarle, Philomena Colucci, Sonia Ioannidis, Lulu Cheng, Umberto Vitolo
Institutions: The University of Texas MD Anderson Cancer Center, University Hospital Münster, Charles University, Rocky Mountain Cancer Centers, Mayo Clinic, Nottingham University Hospitals NHS Trust, University of Nottingham, Fondazione IRCCS Istituto Nazionale dei Tumori, Universitätsklinikum Würzburg, Hollywood Private Hospital, St. Luke's Medical Center, Dong-A University, University of Würzburg, University of Turin, European Institute of Oncology, Incyte (United States), Candiolo Cancer Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7204736454